Small scale, big potential: With the new NOBLYST F product family, the Catalysts Business Line is bringing new momentum to pharmaceutical manufacturing. These precious‑metal catalysts were specifically developed for flow applications in microreactors and make it possible to produce both small quantities—such as for clinical studies—and larger batches efficiently and sustainably.
Flow-Chemistry
Evonik recognizes the paradigm shift toward continuous processing in the pharmaceutical and fine chemicals industries. In response, the company offers cutting‑edge catalysts that are not only highly selective and active but also engineered for optimal filterability—ensuring seamless integration into flow‑chemistry processes.
One major advantage of flow chemistry is that chemical reactions can be controlled and regulated much more precisely than in traditional batch processes. “Flow applications—known technically as flow chemistry—are considered a key technology for pharmaceutical production,” says Katrin Schmidt, Business Development Manager at Catalysts. “They offer real‑time quality control, shorter cycle times, and greater process safety—especially when dealing with hazardous substances or strongly exothermic reactions that release more energy than they absorb.”
With particle sizes of 200 and 600 micrometers, the NOBLYST F series ensures optimal flow and high reactivity. The products closely align with the properties of the precious‑metal catalysts used in batch processes, an area where Catalysts has been successful for many years. This is a major benefit for pharmaceutical manufacturers looking to transition from batch to continuous processing.
Growing demand
Demand for flexible, scalable, and safe continuous production processes is currently rising, especially in China and India. Catalysts is capitalizing on this trend. “We have known our customers’ processes for decades and can support them worldwide with the right catalyst solution—from the laboratory all the way to commercial production,” says Tina Petzold, Global Director Precious Metal Powder Catalysts. “With the NOBLYST F series, we are primarily targeting the pharmaceutical market, but we also see growing interest from the agrochemical and fine chemicals sectors, which have similar process requirements.”
The global market launch began at the end of 2025. A sample kit containing standard samples from the NOBLYST F portfolio helps companies identify the right catalyst. Strategic customers in particular—from Asia, the United States, and Europe—are showing strong interest in the new solutions.